Drug Details
General Information of the Drug (ID: DR7727) | ||||
---|---|---|---|---|
Name |
Ertapenem
|
|||
Synonyms |
Ertapenem; 153832-46-3; Invanz; UNII-G32F6EID2H; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Invanz (TN); G32F6EID2H; C22H25N3O7S; CHEBI:404903; (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Ertapenem (INN); Ertapenem [INN:BAN]; HSDB 8020; (4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CHEMBL1359; SCHEMBL34454; GTPL10906; AOB6700; DTXSID50165456; ZINC3918453; AKOS015895077; AC-6814; DB00303; NCGC00387409-02; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl-4-methyl-7-oxo-, (4R,5S,6S)-; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-; D07908; 832E463; Q553220
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H25N3O7S
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O
|
|||
InChI |
1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1
|
|||
InChIKey |
JUZNIMUFDBIJCM-ANEDZVCMSA-N
|
|||
CAS Number |
CAS 153832-46-3
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
Propolis | Streptophyta | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Escherichia coli isolates NECS892841 | Microorganism model | Escherichia coli | |||
Escherichia coli isolates NECS30090 | Microorganism model | Escherichia coli | ||||
Escherichia coli isolates NECS858785 | Microorganism model | Escherichia coli | ||||
Escherichia coli isolates NECS864598 | Microorganism model | Escherichia coli | ||||
Escherichia coli isolates NEC892420 | Microorganism model | Escherichia coli | ||||
Escherichia coli isolates NEC118564 | Microorganism model | Escherichia coli | ||||
Experimental
Result(s) |
Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Molecule Info | [3] |
